痰基因启动子高甲基化预测吸烟者FEV1下降及全因死亡
在LSC和PLuSS两个独立纵向队列中,痰标本检测12个基因启动子甲基化,评估其对吸烟者FEV1下降及后续肺癌发生的影响。结果显示甲基化基因数目与FEV1下降呈剂量依赖关系,高甲基化与肺癌发生潜伏期缩短及全因死亡更差相关,后续发生肺癌的吸烟者FEV1年下降更快。
要点
- 痰中甲基化基因≥3个的吸烟者FEV1下降速度分别比0-2个者快27.8%(LSC)和10.3%(PLuSS),均P<0.01。
- 痰高甲基化与肺癌发生潜伏期缩短(log-rank P=0.0048)及全因死亡更差(log-rank P<0.0001)相关。
- 后续发生肺癌的吸烟者FEV1年下降比对照吸烟者快5.2 ml(P=0.038)。
核心结论
- 痰中检测的基因甲基化可预测吸烟者的FEV1下降、肺癌发生及全因死亡。
- FEV1快速下降可能是吸烟者肺癌发生的危险因素,或可解释肺癌患者中气道阻塞更常见。
研究设计与样本
- 研究基于两个独立纵向队列:Lovelace吸烟者队列(LSC)和匹兹堡肺癌筛查研究(PLuSS)。
- 采用两阶段嵌套甲基化特异性PCR检测痰中12个基因的甲基化。
- 使用线性混合效应模型评估各变量对FEV1下降的影响。
主要发现
- 甲基化基因数目与FEV1下降呈剂量依赖关系,LSC中≥3个甲基化基因者FEV1下降比0-2个者快27.8%(P<0.01)。
- PLuSS中≥3个甲基化基因者FEV1下降比0-2个者快10.3%(P<0.01)。
- 痰高甲基化与肺癌发生潜伏期缩短相关(log-rank P=0.0048)。
- 痰高甲基化与全因死亡更差相关(log-rank P<0.0001)。
- 后续发生肺癌的吸烟者FEV1年下降比对照吸烟者快5.2 ml(P=0.038)。
关键数值与推荐
- 甲基化基因数目≥3个的吸烟者FEV1下降速度在LSC中快27.8%,在PLuSS中快10.3%,均P<0.01。
- 高甲基化与肺癌发生潜伏期缩短相关,log-rank P=0.0048。
- 高甲基化与全因死亡更差相关,log-rank P<0.0001。
- 后续发生肺癌的吸烟者FEV1年下降比对照快5.2 ml,P=0.038。
临床怎么用
- 对吸烟者可通过痰标本检测基因启动子甲基化,辅助识别FEV1快速下降及肺癌高风险个体。
- 痰高甲基化提示需更密切监测肺功能下降及肺癌发生风险。
- FEV1快速下降的吸烟者应视为肺癌高风险人群,加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Gene promoter hypermethylation detected in sputum assesses the extent of field cancerization and predicts lung cancer (LC) risk in ever-smokers. A rapid decline of FEV1 is a major driver for development of airway obstruction. OBJECTIVES: To assess the effects of methylation of 12 genes on FEV1 decline and of FEV1 decline on subsequent LC incidence using two independent, longitudinal cohorts (i.e., LSC [Lovelace Smokers Cohort] and PLuSS [Pittsburgh Lung Screening Study]). METHODS: Gene methylation was measured in sputum using two-stage nested methylation-specific PCR. The linear mixed effects model was used to assess the effects of studied variables on FEV1 decline. MEASUREMENTS AND MAIN RESULTS: A dose-dependent relationship between number of genes methylated and FEV1 decline was identified, with smokers with three or more methylated genes having 27.8% and 10.3% faster FEV1 decline than smokers with zero to two methylated genes in the LSC and PLuSS cohort, respectively (all P < 0.01). High methylation in sputum was associated with a shorter latency for LC incidence (log-rank P = 0.0048) and worse all-cause mortality (log-rank P < 0.0001). Smokers with subsequent LC incidence had a more rapid annual decline of FEV1 (by 5.2 ml, P = 0.038) than smoker control subjects. CONCLUSIONS: Gene methylation detected in sputum predicted FEV1 decline, LC incidence, and all-cause mortality in smokers. Rapid FEV1 decline may be a risk factor for LC incidence in smokers, which may explain a greater prevalence of airway obstruction seen in patients with LC.
引用
- Leng S, Diergaarde B, Picchi MA, et al. Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med. 2018. PMID: 29437466. doi:10.1164/rccm.201708-1659OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。